Incyte Corporation
Incyte reports Q1 2024 financial results and key updates
Summary
Incyte Corporation reported its 2024 first quarter financial results on April 30, 2024, with total revenues of $881 million, representing a 9% increase year-over-year. The company announced net product revenues for Jakafi at $572 million, showing a 1% decrease Y/Y, and Opzelura saw net product revenues of $86 million, a 52% increase Y/Y. Incyte also provided updates on its clinical pipeline and entered into an agreement to acquire Escient Pharmaceuticals. The company's GAAP net income for Q1 2024 was $169.5 million, with a GAAP EPS of $0.76 and Non-GAAP EPS of $0.65.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement